Future therapies in the GLP-1 pipeline include more effective new drugs like dual-action agonists, oral pill versions for weight loss, and combination therapies designed to preserve muscle mass during weight loss
Among the identified autoantibodies produced in MS cases, currently only the anti-MOG IgG has been identified as clinically relevant, given that anti-MOG disease has emerged as a new clinical entity altogether (74, 75)
Potential complementary evidence of GLP-1RAs and SGLT2is In a meta-analysis comparing the effects of GLP-1RAs with SGLT2is, five GLP-1RA (ELIXA, LEADER, SUSTAIN-6, EXSCEL, and Harmony Outcomes) and three SGLT2i trials (EMPA-REG OUTCOME, CANVAS Program, and DECLARE-TIMI 58) with a total of 77,242 patients were include [35]
The data examined in this report show that most commercial patients face significant hurdles: large denial rates (often two-thirds of requests), multi-day delays (median ~6 days if not instant-approve), and high first-fill abandonment (fill rates commonly 60%)